21-Deacetoxy Deflazacort

IMPURITIES

Product Details

CAT No.# CS-T-51622
Category Impurities
CAS 13649-88-2
Molecular Weight 383.48
Molecular Formula C23H29NO4
Stock Status: In-Stock
Purity: 99.98
Melting Point: >250
Solubility: Chloroform
Appearance: Pale Beige Solid
Synonyms: 21-Deacetoxy Deflazacort;Desacetoxy Deflazacort;(11β,16β)-11-hydroxy-2-methyl-5H-Pregna-1,4-dieno[17,16-d]oxazole-3,20-dione; (11β,16β)-11β-hydroxy-2-methyl-5βH-Pregna-1,4-dieno[17,16-d]oxazole-3,20-dione; 11β-hydroxy-2-
Application Notes: Impurity in commercial preparations of Deflazacort
References: NathansHydroxyn, G., et al.: J. Med. Chem., 10,799 (1967), Schiatti, P., et al.: Arzneim. Forsch., 30, 1543 (1980), Cavall-Perin, P., et al.: Eur. J. Clin. Pharmacol., 26, 357 (1984), Imbimbo, B., et al.: Adv. Exp. Med. Biol., 171, 241 (1984),
Storage: For long term usage store at 2-8°C
COA / MSDS:    View COA    MSDS    Enquire
The balance used are calibrated with weights traceable to National Standards NIST for accuracy
PEOPLE ALSO SEARCHED FOR: 1. (6R,7S)-7-(2-chloroacetamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
2. propan-2-yl-5-hydroxy-2-methyl-2-4-(3-nitrophenyl)-6-oxo-1,4,5,5-tetraahydropyridine-3-carboxylate
3. ([13C6]Leu5)-Ghrelin (human) (H-7252.1000)
4. Benidipine D7
5. Lauroside D
6. Triazolam 13C D3
7. Icatibant impurity 1
8. BISPHENOL AF (RING-13C12)
9. 0.1% TFA in Water ULC-MS
10. Metamizole EP Impurity C HCl
11. Silodosin Metabolite D4
12. Brivaracetam Carboxylic acid metabolite [UCB 42145]
13. Terbuthylazine D5
14. tibolone (848)
15. (Z)-Dimethylvinphos
16. Silodosin Metabolite
17. 2-Phenoxymethanesulfonanilide
18. Nimesulide EP Impurity A
19. Acetone HPLC
20. Nandrolone Decanoate EP impurity F


SMILES:
CC([C@]([C@@]1([H])C[C@@]2([H])[C@@](CCC3=CC4=O)([H])[C@]([C@]3(C=C4)C)([H])[C@@H](O)C5)(N=C(C)O1)[C@]25C)=O



This page contains information about 21-Deacetoxy Deflazacort Cas 13649-88-2 and its Impurities.
"Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk."